Novel Integration of New prostate radiation therapy schedules with adJuvant Androgen deprivation

In men with intermediate and high-risk prostate cancer, the NINJA trial is looking at comparing two different radiotherapy treatment schedules called stereotactic body radiotherapy (SBRT). The aim is to develop better methods of treatment for prostate cancer using this type of treatment, and further understand what causes some of the side effects of treatments. It is hoped this research will potentially improve the accuracy and quality of radiotherapy treatment in prostate cancer.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Participating Centres

Accrual Target

472

Current Accrual

Trial Chairperson

Prof Jarad Martin, Calvary Mater Hospital, NSW, Australia

Dr Mark Sidhom, Liverpool Hospital, NSW, Australia

Trial Contact

chc-calvarymater-ninjatrial@health.nsw.gov.au

Clinical Trial Registration

Related Post

4 June, 2026

Report showcases a year of impactful research, collaboration and consumer engagement

LATEST NEWS: 4 June 2025 TROG’s latest Annual Research

ESTRO26 presentation
20 May, 2026

TROG trials in the spotlight at ESTRO26 international conference

LATEST NEWS: 20 MAY A number of TROG trials